FDA Approves Novo Nordisk's Victoza

The U.S. Food and Drug Administration today approved Victoza (liraglutide), a once-daily injection to treat type 2 diabetes in some adults.

Victoza is intended to help lower blood sugar levels along with diet, exercise, and selected other diabetes medicines. It is not recommended as initial therapy in patients who have not achieved adequate diabetes control on diet and exercise alone.

Insulin is a hormone that helps prevent sugar (glucose) from building up in the blood. People with type 2 diabetes have difficulty making and using insulin. Victoza is in a class of medicines known as glucagon-like peptide-1 (GLP-1) receptor agonists that help the pancreas make more insulin after eating a meal.

The FDA has approved Victoza (liraglutide), a once-daily injection to treat type 2 diabetes in adults.

Victoza is intended to help lower blood sugar levels along with diet, exercise, and selected other diabetes medicines. It isn't recommended as the first therapy patients try if they haven't adequately controlled their diabetes with diet and exercise alone.

Victoza belongs to a class of medicines known as glucagon-like peptide-1 (GLP-1) receptor agonists, which help the pancreas make more insulin after eating a meal.

Victoza® (liraglutide) is a prescription medication approved to help control blood sugar -- when used in combination with diet and exercise -- in people with type 2 diabetes. It is a once-daily, noninsulin, injectable medication.

Victoza is a diabetes medicine that helps control blood sugar levels. It works by increasing the amount of insulin that your body produces.

Victoza is used to treat type 2 diabetes (non-insulin dependent). This medication is not for treating type 1 diabetes.